Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

PA.6 (ACCORD 24), A Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) In Patients With Resected Pancreatic Adenocarcinoma, was closed to accrual on September 7, 2016.

The target sample size of 390 was met and Canadian sites contributed 93 participants.

PRC.4 (ALLIANCE A031201), Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer, will soon meet its accrual goal and was closed to accrual on August 31, 2016.

LYC.1 (ECOG 1411), Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV->R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB->LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV->LR)), will be officially closed to further accrual as of 5:00 pm EST today, September 9, 2016.

Thank you to all participating centres, staff and patients for contributing to the success of these trials.